CBD: research and patient questions (Page 3)

Clinicians should be cautious when prescribing CBD-dominant cannabis products, as they may produce stronger adverse effects than expected. Understanding cannabinoid interactions is crucial for safe therapeutic use.

Clinicians should be aware that while CBD may increase the psychoactive effects of THC, it does not enhance its analgesic properties. Careful consideration of dosing is essential when combining these cannabinoids.

Sublingual THC:CBD oil extracts administered at modest, individually titrated daily doses (around 20 mg each) provided statistically significant, modest long-term improvements in chronic pain and associated disease burden (sleep, anxiety, and quality of life) with a reasonable safety profile. However, nearly 40% of patients dropped out by 6 months, and clinician monitoring for CNS and GI side effects remains essential.

While current systemic and oral cannabinoid formulations lack robust evidence for managing acute orofacial and post-operative dental pain, topical transdermal CBD demonstrates potential for localized myofascial temporomandibular disorder pain. Integrative clinicians should prioritize conventional first-line agents like NSAIDs for acute dental pain while awaiting higher-quality trials on localized topical cannabinoid therapies.

Administering 20 mg of isolated cannabinol (CBN) nightly can effectively reduce nighttime awakenings and overall sleep disturbance in patients with subjective sleep difficulties without causing daytime fatigue or severe adverse events. Interestingly, combining CBD with CBN did not enhance efficacy and may potentially attenuate its sleep-promoting benefits, suggesting clinicians should consider isolated CBN rather than complex CBD/CBN ratios for sleep support.

Consider recommending CBD-dominant cannabis for patients with anxiety symptoms, as it may provide greater relief compared to THC-dominant options.

It helped: The new powder form led to higher levels of cannabinoids in the blood and reached those peaks much faster than standard oil drops, while both versions were well tolerated.

Clinicians should consider the route of administration when prescribing THC:CBD formulations, as bioavailability may vary significantly between methods.

In this double-blind laboratory study, low-dose oral cannabidiol (50 mg) enhanced the acute analgesic properties of 4 mg hydromorphone without increasing negative subjective effects or adverse events, whereas higher CBD doses (200 mg) increased adverse effects. CBD also successfully mitigated the psychomotor impairment caused by the opioid alone. These findings suggest that lower-dose CBD may hold clinical potential as an opioid-sparing adjunct for acute pain management.

Integrative physicians should consider cannabis as a potential treatment for sleep disorders, while paying close attention to dosing to maximize benefits and minimize risks.